<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="714">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>26/09/2005</approvaldate>
  <actrnumber>ACTRN12605000515695</actrnumber>
  <trial_identification>
    <studytitle>Open label longitudinal study of Botox and chronic pelvic pain 03/102</studytitle>
    <scientifictitle>To assess response to Botox injections of the pelvic floor in women with documented pelvic floor muscle spasm with regards to pain, quality of life and anxiety state and to determine an efficacy curve and dosage intervals for repeat injections.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Chronic pelvic pain</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Fifty-seven women who have completed the original RCT protocol are eligible to participate in this study. All women will receive 100 IU Botox diluted in 4.4 ml normal saline (25 IU units in 1.0 ml) and injected at four (4) sites in the pubococcygeus and puborectalis muscles bilaterally. They will be assessed at baseline, one month post injection, three months post injection and six months post injection.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess response to Botox injections of the pelvic floor in women with documented pelvic floor muscle spasm with regards to pain</outcome>
      <timepoint>At baseline, week four, week twelve and week twenty-six.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess response to Botox injections of the pelvic floor in women with documented pelvic floor muscle spasm with regards to quality of life</outcome>
      <timepoint>At baseline, week four, week twelve and week twenty-six.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess response to Botox injections of the pelvic floor in women with documented pelvic floor muscle spasm with regards to anxiety state</outcome>
      <timepoint>At baseline, week four, week twelve and week twenty-six.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Duration of efficacy</outcome>
      <timepoint>Assessment at 6-monthly intervals after 26 weeks will be requested.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome />
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1) History of chronic pelvic pain for two or more years (2) Documented pelvic floor hypertonicity, with at least two of the following: Muscular myalgia on palpation(3) A pelvic floor resting manometry reading of &gt;40cm water(4) Pelvic pain that significantly alters quality of life(5)Willing to attend the Department of Endo-Gynaecology and comply with the study requirements for the duration of the study period i.e., 26 weeks. Assessment at 6-monthly intervals after this time will be requested to determine duration of efficacy.   (6)Age 18 to 55(7)Has completed the protocol for the RCT, study reference number 03/102</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1)Current pregnancy (documented by pregnancy test) or a desire for pregnancy in the six months following injection (2)Inability to tolerate vaginal pelvic floor muscle examination, manometry and/or EMG.(3)Significant medical and or psycho-social problems(4)Breast feeding (5)Not willing to use a reliable method of contraception (e.g. barrier methods, the oral contraceptive pill, Depo Provera or other similar depot progestogen or intra- uterine contraceptive device)(6)Poor comprehension of written and spoken English (7)Contraindications for the use of Botox injections. ie: known hypersensitivity to the formulation of Botox. (8)Current use of aminoglycoside antibiotics(9)History of neuro-muscular and/or bleeding disorder.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>none</concealment>
    <sequence>none</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>19/04/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>58</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Allergan Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>: To assess response to Botox injections of the pelvic floor in women with documented pelvic floor muscle spasm with regards to pain, quality of life and anxiety state and to determine an efficacy curve and dosage intervals for repeat injections.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South eastern and Illawarra Area Health Service, Eastern Division</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ms Sherin Jarvis</name>
      <address>Department of Endogynaecology
Royal Hospital for Women
Level 2
Barker Street
Randwick NSW 2031</address>
      <phone>+61 2 93826557</phone>
      <fax>+61 2 93826244</fax>
      <email>Jarviss@sesahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Sherin Jarvis</name>
      <address>Department of Endogynaecology
Royal Hospital for Women
Level 2
Barker Street
Randwick NSW 2031</address>
      <phone>+61 2 93826557</phone>
      <fax>+61 2 93826244</fax>
      <email>Jarviss@sesahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>